Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NAMS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNewAmsterdam COO Douglas Kling resigns to become CEO of another biotech
Filed July 22, 2026 · Period ending July 16, 2026 · ~1 min read
Key Changes
-
medium
Chief Operating Officer Douglas Kling resigned effective August 14, 2026, to become CEO of another clinical-stage biotech company. He will continue as an advisor on the PREVAIL obicetrapib trial and other programs.
Item 5.02 verify on EDGAR →
Summary
NewAmsterdam Pharma disclosed that Chief Operating Officer Douglas Kling will resign effective August 14, 2026, to take a CEO position at another clinical-stage biotech company. The company plans to enter into a separation agreement and an advisor agreement under which Kling will provide transition and advisory services related to the PREVAIL clinical trial of obicetrapib and other clinical programs, though terms remain subject to mutual agreement. For retail holders, this is a routine executive departure with limited immediate impact.
Kling is moving to a CEO role elsewhere—a career advancement rather than a departure signaling internal issues. The planned advisory arrangement suggests continuity on key clinical programs during the transition. The company will disclose the material terms of both agreements in an amendment once finalized.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The Company also expects to enter into an advisor agreement with Mr. Kling pursuant to which he will provide transition and advisory services related to the Company’s PREVAIL clinical trial of obicetrapib and other clinical programs, subject to mutual agreement of terms.
Following his departure, Kling will continue to support the Company as an advisor, specifically assisting with the PREVAIL clinical trial of obicetrapib and other clinical programs. The material terms of both the separation agreement and advisor agreement will be disclosed in an amendment to this 8-K once finalized.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 28, 2026 · How we verify